SC
RXRX icon

Shay Capital’s Recursion Pharmaceuticals RXRX Stock Holding History

Shay Capital’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$220K Sell
59,841
-100,000
-63% -$333K 0.01% 396
2026
Q1 		$491K Sell
159,841
-120,000
-43% -$464K 0.04% 275
2025
Q4 		$1.14M Buy
279,841
+231,530
+479% +$1.15M 0.12% 167
2025
Q3 		$236K Buy
+48,311
New +$254K 0.02% 332

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Shay Capital's RXRX Position: Q2 2026 in Review

Shay Capital reduced its Recursion Pharmaceuticals (RXRX) stake by 63% in Q2 2026, selling an estimated $333K and leaving 59,841 shares worth $220K. The position accounts for 0.01% of the portfolio, ranked #396.

Shay Capital first reported a position in RXRX in Q3 2025 and has held it in 4 quarters since. The position peaked at $1.14M in Q4 2025. 342 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Shay Capital held 59,841 shares of Recursion Pharmaceuticals worth $220K as of Q2 2026.
  • Shay Capital sold 100,000 Recursion Pharmaceuticals shares in Q2 2026, an estimated $333K.
  • Recursion Pharmaceuticals made up 0.01% of Shay Capital's portfolio in Q2 2026, its #396 holding.
  • Shay Capital first reported a position in Recursion Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • Shay Capital's Recursion Pharmaceuticals position peaked at $1.14M in Q4 2025.
  • 342 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Shay Capital's 13F filing for Q2 2026, filed 14 Aug 2026.